Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine
2. Tak 438
3. Tak-438
4. Tak438
5. Vonoprazan
1. Tak-438
2. 1260141-27-2
3. 881681-01-2
4. Vonoprazan Fumurate
5. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Fumarate
6. Tak 438
7. Tak-438 Monofumarate
8. Vonoprazan Monofumarate
9. Vonoprazan Fumarate (tak-438)
10. 4qw3x4amlb
11. Tak438
12. Unii-4qw3x4amlb
13. Takecab
14. Vocinti
15. (e)-but-2-enedioic Acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-n-methylmethanamine
16. 1h-pyrrole-3-methanamine, 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-, (2e)-2-butenedioate (1:1)
17. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Xfumarate
18. 1h-pyrrole-3-methanamine, 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-, 2-butenedioate (1:1)
19. Mfcd18633280
20. Vonoprazan Monofumurate
21. 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine Fumarate
22. Takecab (tn)
23. Vonoprazan Fumarate [usan]
24. Schembl194394
25. Schembl194396
26. Chembl2064032
27. Vonoprazan Fumarate [mi]
28. Vonoprazan Fumarate (jan/usan)
29. Ex-a097
30. Vonoprazan Fumarate [jan]
31. Bcp05635
32. Bcp13238
33. Ex-a4001
34. S8016
35. Vonoprazan Fumarate [who-dd]
36. Akos027251052
37. Ccg-269350
38. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Monofumarate
39. 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-1h-pyrrole-3-methanamine (2e)-2-butenedioate
40. Ac-29287
41. Ac-29309
42. Ds-12234
43. Ls-14849
44. Cs-0164592
45. Sw220126-1
46. D10466
47. A854789
48. A900258
49. J-524312
50. Q25104163
51. Tak438 Fumarate;tak-438 Fumarate;tak 438 Fumarate;1260141-27-2
52. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Fumarate? (vonoprazan Impurity Pound(c)
53. 2098974-13-9
54. 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-1h-pyrrole-3-methanamine 2-butenedioate
| Molecular Weight | 461.5 g/mol |
|---|---|
| Molecular Formula | C21H20FN3O6S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 461.10568470 g/mol |
| Monoisotopic Mass | 461.10568470 g/mol |
| Topological Polar Surface Area | 147 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 629 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
API SUPPLIERS
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Click Us!
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35150
Submission : 2020-08-31
Status : Active
Type : II
NDC Package Code : 42765-014
Start Marketing Date : 2020-08-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2025-01-24
Registration Number : Su289-26-ND
Manufacturer Name : Metrochem API Private Limited
Manufacturer Address : Plot No. 34B, 40B & 60B, JN Pharma City, Thanam Village, Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40356
Submission : 2024-12-29
Status : Active
Type : II
| Available Reg Filing : BR |
China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39107
Submission : 2023-11-02
Status : Active
Type : II
Date of Issue : 2024-01-15
Valid Till : 2027-01-14
Written Confirmation Number : SD240003
Address of the Firm :
Registrant Name : Farmia Co., Ltd.
Registration Date : 2025-01-23
Registration Number : Su719-2-ND
Manufacturer Name : Shandong Chenghui Shuangda Pharmaceutical Co.,Ltd.
Manufacturer Address : Economic Development Zone,Pingyuan County, DezhouCity, Shandong, PRChina
Neuland Laboratories- A dedicated 100% API provider.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39528
Submission : 2024-02-29
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Evonik Health Care is the innovation hub for leading life science companies
NDC Package Code : 52696-0010
Start Marketing Date : 2023-11-21
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
With Virupaksha, you get a quality product with on-time delivery.
Date of Issue : 2025-10-01
Valid Till : 2028-09-30
Written Confirmation Number : WC-0191
Address of the Firm :
AMI Lifesciences is Driven by Chemistry. Powered by People.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36262
Submission : 2021-09-06
Status : Active
Type : II
Date of Issue : 2025-08-05
Valid Till : 2028-06-25
Written Confirmation Number : WC-0054
Address of the Firm :
Registrant Name : Jinyang Pharmaceutical Co., Ltd.
Registration Date : 2025-10-10
Registration Number : Su69-12-ND(1)
Manufacturer Name : Ami Lifesciences Private Limited
Manufacturer Address : Block No. 82/B, ECP Road At & Post. Karakhadi, Tal-Padra, City : Karakhadi-391450, Dist : Vadodara, Gujarat State India
| Available Reg Filing : BR, CN |
HRV Pharma - Market Expansion Leader in Pharmaceuticals.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Voquezna Triple Pack
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Phathom Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 24, 2022
Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Phathom Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan
Details : Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Product Name : Voquezna Triple Pack
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 24, 2022
Details:
The proceeds from the offering will be used to fund the clinical development of Vonoprazan, a miscellaneous product targeting Potassium-transporting ATPase, to address Eosinophilic Esophagitis.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Voquezna
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering January 07, 2026
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Undisclosed
Deal Type : Public Offering
Phathom Pharmaceuticals Plans Public Offering of Common Stock and Warrants
Details : The proceeds from the offering will be used to fund the clinical development of Vonoprazan, a miscellaneous product targeting Potassium-transporting ATPase, to address Eosinophilic Esophagitis.
Product Name : Voquezna
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 07, 2026
Details:
Vonoprazan is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Gastritis.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 12, 2025
Lead Product(s) : Vonoprazan Fumarate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vono...
Details : Vonoprazan is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Gastritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2025
Details:
Voquezna Triple Pak (vonoprazan) is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Helicobacter Infections.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Voquezna Triple Pak
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Phathom Pharmaceuticals | NRG Oncology
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2025
Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Phathom Pharmaceuticals | NRG Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
Details : Voquezna Triple Pak (vonoprazan) is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Helicobacter Infections.
Product Name : Voquezna Triple Pak
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2025
Details:
Voquezna (vonoprazan) is a potassium-competitive acid blocker, indicated for heartburn associated with Non-Erosive GERD.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Voquezna
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2025
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phathom Gets FDA Nod for 10 Years of Regulatory Exclusivity for Voquezna
Details : Voquezna (vonoprazan) is a potassium-competitive acid blocker, indicated for heartburn associated with Non-Erosive GERD.
Product Name : Voquezna
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2025
Details:
Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Eosinophilic Esophagitis.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 28, 2025
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Eosinophilic Esophagitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 28, 2025
Details:
Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 18, 2025
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2025
Details:
Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Stomach Ulcer.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Stomach Ulcer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2024
Details:
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Lupivon (vonoprazan), a novel potassium-competitive acid blocker, in India.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Lupivon
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 18, 2024
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin Partners with Takeda to Commercialise Vonoprazan
Details : Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Lupivon (vonoprazan), a novel potassium-competitive acid blocker, in India.
Product Name : Lupivon
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 18, 2024
Details:
The licensing deal will enhance Alkem's offerings in the gastrointestinal segment by including Vonzai (vonoprazan), a first-in-class potassium-competitive acid blocker.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Vonzai
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Alkem Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 03, 2024
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Alkem Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Alkem Inks Licensing Pact with Takeda to Introduce Vonoprazan in India
Details : The licensing deal will enhance Alkem's offerings in the gastrointestinal segment by including Vonzai (vonoprazan), a first-in-class potassium-competitive acid blocker.
Product Name : Vonzai
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 03, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
36
PharmaCompass offers a list of Vonoprazan Fumarate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vonoprazan Fumarate manufacturer or Vonoprazan Fumarate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vonoprazan Fumarate manufacturer or Vonoprazan Fumarate supplier.
PharmaCompass also assists you with knowing the Vonoprazan Fumarate API Price utilized in the formulation of products. Vonoprazan Fumarate API Price is not always fixed or binding as the Vonoprazan Fumarate Price is obtained through a variety of data sources. The Vonoprazan Fumarate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Takecab (TN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Takecab (TN), including repackagers and relabelers. The FDA regulates Takecab (TN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Takecab (TN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Takecab (TN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Takecab (TN) supplier is an individual or a company that provides Takecab (TN) active pharmaceutical ingredient (API) or Takecab (TN) finished formulations upon request. The Takecab (TN) suppliers may include Takecab (TN) API manufacturers, exporters, distributors and traders.
click here to find a list of Takecab (TN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Takecab (TN) DMF (Drug Master File) is a document detailing the whole manufacturing process of Takecab (TN) active pharmaceutical ingredient (API) in detail. Different forms of Takecab (TN) DMFs exist exist since differing nations have different regulations, such as Takecab (TN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Takecab (TN) DMF submitted to regulatory agencies in the US is known as a USDMF. Takecab (TN) USDMF includes data on Takecab (TN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Takecab (TN) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Takecab (TN) suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Takecab (TN) Drug Master File in Korea (Takecab (TN) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Takecab (TN). The MFDS reviews the Takecab (TN) KDMF as part of the drug registration process and uses the information provided in the Takecab (TN) KDMF to evaluate the safety and efficacy of the drug.
After submitting a Takecab (TN) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Takecab (TN) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Takecab (TN) suppliers with KDMF on PharmaCompass.
A Takecab (TN) written confirmation (Takecab (TN) WC) is an official document issued by a regulatory agency to a Takecab (TN) manufacturer, verifying that the manufacturing facility of a Takecab (TN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Takecab (TN) APIs or Takecab (TN) finished pharmaceutical products to another nation, regulatory agencies frequently require a Takecab (TN) WC (written confirmation) as part of the regulatory process.
click here to find a list of Takecab (TN) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Takecab (TN) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Takecab (TN) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Takecab (TN) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Takecab (TN) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Takecab (TN) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Takecab (TN) suppliers with NDC on PharmaCompass.
Takecab (TN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Takecab (TN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Takecab (TN) GMP manufacturer or Takecab (TN) GMP API supplier for your needs.
A Takecab (TN) CoA (Certificate of Analysis) is a formal document that attests to Takecab (TN)'s compliance with Takecab (TN) specifications and serves as a tool for batch-level quality control.
Takecab (TN) CoA mostly includes findings from lab analyses of a specific batch. For each Takecab (TN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Takecab (TN) may be tested according to a variety of international standards, such as European Pharmacopoeia (Takecab (TN) EP), Takecab (TN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Takecab (TN) USP).
